Toll-Like Receptor 7 Agonist Therapy with Imidazoquinoline Enhances Cancer Cell Death and Increases Lymphocytic Infiltration and Proinflammatory Cytokine Production in Established Tumors of a Renal Cell Carcinoma Mouse Model
Figure 1
Generation of four mouse treatment groups. mice harboring RENCA RCC tumor xenografts were randomized on day 0 and again on day 7 to treatment with either 3M011 imidazoquinoline or placebo. Four treatment groups () were thus generated based on day 0/day 7 treatments: (I) 3M011/3M011, (II) 3M011/placebo, (III) placebo/3M011, and (IV) placebo/placebo.
